Logo image of ARCT

ARCTURUS THERAPEUTICS HOLDIN (ARCT) Stock Overview

NASDAQ:ARCT - US03969T1097 - Common Stock

17.3 USD
+0.01 (+0.06%)
Last: 8/28/2025, 8:00:00 PM
17.2 USD
-0.1 (-0.58%)
After Hours: 8/28/2025, 8:00:00 PM

ARCT Key Statistics, Chart & Performance

Key Statistics
52 Week High25.88
52 Week Low8.04
Market Cap469.69M
Shares27.15M
Float25.02M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2.23
PEN/A
Fwd PEN/A
Earnings (Next)11-05 2025-11-05/amc
IPO05-22 2013-05-22
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


ARCT short term performance overview.The bars show the price performance of ARCT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20 30 40

ARCT long term performance overview.The bars show the price performance of ARCT in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 -40

The current stock price of ARCT is 17.3 USD. In the past month the price increased by 41.69%. In the past year, price decreased by -18.01%.

ARCTURUS THERAPEUTICS HOLDIN / ARCT Daily stock chart

ARCT Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.63 367.30B
AMGN AMGEN INC 13.1 153.76B
GILD GILEAD SCIENCES INC 14.54 139.67B
VRTX VERTEX PHARMACEUTICALS INC 23.14 100.52B
REGN REGENERON PHARMACEUTICALS 12.7 61.43B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.29B
ARGX ARGENX SE - ADR 75.95 43.09B
ONC BEONE MEDICINES LTD-ADR 6.02 35.42B
INSM INSMED INC N/A 28.53B
BNTX BIONTECH SE-ADR N/A 24.50B
NTRA NATERA INC N/A 23.04B
BIIB BIOGEN INC 8.29 19.45B

About ARCT

Company Profile

ARCT logo image Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. The company is headquartered in San Diego, California and currently employs 174 full-time employees. The company went IPO on 2013-05-22. The firm with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. The company has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The firm's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.

Company Info

ARCTURUS THERAPEUTICS HOLDIN

10628 Science Center Dr Ste 250

San Diego CALIFORNIA 92121 US

CEO: Joseph E. Payne

Employees: 175

ARCT Company Website

ARCT Investor Relations

Phone: 18589002660

ARCTURUS THERAPEUTICS HOLDIN / ARCT FAQ

What is the stock price of ARCTURUS THERAPEUTICS HOLDIN today?

The current stock price of ARCT is 17.3 USD. The price increased by 0.06% in the last trading session.


What is the ticker symbol for ARCTURUS THERAPEUTICS HOLDIN stock?

The exchange symbol of ARCTURUS THERAPEUTICS HOLDIN is ARCT and it is listed on the Nasdaq exchange.


On which exchange is ARCT stock listed?

ARCT stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ARCTURUS THERAPEUTICS HOLDIN stock?

18 analysts have analysed ARCT and the average price target is 62.93 USD. This implies a price increase of 263.78% is expected in the next year compared to the current price of 17.3. Check the ARCTURUS THERAPEUTICS HOLDIN stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ARCTURUS THERAPEUTICS HOLDIN worth?

ARCTURUS THERAPEUTICS HOLDIN (ARCT) has a market capitalization of 469.69M USD. This makes ARCT a Small Cap stock.


How many employees does ARCTURUS THERAPEUTICS HOLDIN have?

ARCTURUS THERAPEUTICS HOLDIN (ARCT) currently has 175 employees.


What are the support and resistance levels for ARCTURUS THERAPEUTICS HOLDIN (ARCT) stock?

ARCTURUS THERAPEUTICS HOLDIN (ARCT) has a support level at 17.29 and a resistance level at 19.4. Check the full technical report for a detailed analysis of ARCT support and resistance levels.


Is ARCTURUS THERAPEUTICS HOLDIN (ARCT) expected to grow?

The Revenue of ARCTURUS THERAPEUTICS HOLDIN (ARCT) is expected to decline by -43.54% in the next year. Check the estimates tab for more information on the ARCT EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ARCTURUS THERAPEUTICS HOLDIN (ARCT) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ARCTURUS THERAPEUTICS HOLDIN (ARCT) stock pay dividends?

ARCT does not pay a dividend.


When does ARCTURUS THERAPEUTICS HOLDIN (ARCT) report earnings?

ARCTURUS THERAPEUTICS HOLDIN (ARCT) will report earnings on 2025-11-05, after the market close.


What is the Price/Earnings (PE) ratio of ARCTURUS THERAPEUTICS HOLDIN (ARCT)?

ARCTURUS THERAPEUTICS HOLDIN (ARCT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.23).


What is the Short Interest ratio of ARCTURUS THERAPEUTICS HOLDIN (ARCT) stock?

The outstanding short interest for ARCTURUS THERAPEUTICS HOLDIN (ARCT) is 17.47% of its float. Check the ownership tab for more information on the ARCT short interest.


ARCT Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to ARCT. When comparing the yearly performance of all stocks, ARCT turns out to be only a medium performer in the overall market: it outperformed 64.92% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ARCT Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to ARCT. No worries on liquidiy or solvency for ARCT as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ARCT Financial Highlights

Over the last trailing twelve months ARCT reported a non-GAAP Earnings per Share(EPS) of -2.23. The EPS increased by 13.23% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -19.45%
ROE -26.04%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%46.88%
Sales Q2Q%-43.24%
EPS 1Y (TTM)13.23%
Revenue 1Y (TTM)-25.46%

ARCT Forecast & Estimates

18 analysts have analysed ARCT and the average price target is 62.93 USD. This implies a price increase of 263.78% is expected in the next year compared to the current price of 17.3.

For the next year, analysts expect an EPS growth of 13.95% and a revenue growth -43.54% for ARCT


Analysts
Analysts86.67
Price Target62.93 (263.76%)
EPS Next Y13.95%
Revenue Next Year-43.54%

ARCT Ownership

Ownership
Inst Owners91.62%
Ins Owners0.81%
Short Float %17.47%
Short Ratio7.95